GlycoMimetics, Inc. GLYC
Set alert
15.71 0.00 0.00%
As of Jul 2, 3:58 PM ET
15.52 Day range 17.39
52-week range unavailable
- YTD
- -36.93%
- 1 year
- -41.94%
- Open
- 16.25
- Prev close
- 15.71
- Mkt cap
- 13.96M
- Vol
- 612
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.52
- High
- 17.39
- Forward P/E
- -2.41
- Beta
- 1.84
- Short ratio
- 1.07
- Inst. own
- 47.91%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 2, 2024
- 50-d avg
- 0.2958
- 200-d avg
- 0.6851
- 1y target
- 1.00
2Y chart
Events in this range
- Aug 2, 2023Earnings: -0.13; estimate -0.18; surprise 27.78%
- Aug 3, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Nov 3, 2023Earnings: -0.14; estimate -0.14; surprise 0%
- Dec 22, 2023Rating: Capital One · — → Overweight
- Mar 27, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Mar 27, 2024Earnings: -0.14; estimate -0.15; surprise 6.67%
- May 6, 2024Downgrade: HC Wainwright & Co. · Buy → Neutral
- May 9, 2024Earnings: -0.17; estimate -0.16; surprise -6.25%
- Jun 4, 2024Rating: HC Wainwright & Co. · — → Neutral
- Jul 26, 2024Downgrade: TD Cowen · Buy → Hold
- Oct 2, 2024Earnings: —; estimate -0.16; surprise —%
- Nov 13, 2024Earnings: -0.15; estimate 0; surprise —%
- Jun 16, 2025Split: 1 for 100
Signals (97)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| RSI: Oversold | Jun 9, 2025 | 1 year ago |
| SMA: Bearish | May 27, 2025 | 1 year ago |
| SMA: Bearish | May 23, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| SMA: Bearish | May 14, 2025 | 1 year ago |
| SMA: Bearish | May 14, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bullish | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 30, 2025 | 1 year ago |
| SMA: Bearish | Apr 29, 2025 | 1 year ago |
| SMA: Bearish | Apr 29, 2025 | 1 year ago |
| SMA: Bullish | Apr 24, 2025 | 1 year ago |
| SMA: Bullish | Apr 24, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| SMA: Bearish | Mar 26, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| SMA: Bearish | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 19, 2025 | 1 year ago |
| SMA: Bearish | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 7, 2025 | 1 year ago |
| SMA: Bearish | Mar 6, 2025 | 1 year ago |
| SMA: Bullish | Mar 5, 2025 | 1 year ago |
| SMA: Bullish | Mar 5, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| RSI: Overbought | Feb 18, 2025 | 1 year ago |
| SMA: Bullish | Feb 14, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 12, 2025 | 1 year ago |
| SMA: Bullish | Feb 11, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| SMA: Bullish | Jan 30, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Dec 11, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 15, 2024 | 1 year ago |
| RSI: Overbought | Oct 29, 2024 | 2 years ago |
| SMA: Bullish | Oct 23, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 15, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 9, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 15, 2024 | 2 years ago |
| RSI: Oversold | Aug 5, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 30, 2024 | 2 years ago |
| SMA: Bearish | Jul 25, 2024 | 2 years ago |
| SMA: Bullish | Jul 16, 2024 | 2 years ago |
| MACD: Buy Signal | May 21, 2024 | 2 years ago |
| RSI: Oversold | May 6, 2024 | 2 years ago |
| RSI: Oversold | Apr 25, 2024 | 2 years ago |
| RSI: Oversold | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 19, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 4, 2024 | 2 years ago |
| SMA: Bearish | Apr 2, 2024 | 2 years ago |
| SMA: Bullish | Mar 27, 2024 | 2 years ago |
| SMA: Bearish | Mar 21, 2024 | 2 years ago |
| SMA: Bullish | Mar 20, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 20, 2024 | 2 years ago |
| SMA: Bearish | Mar 5, 2024 | 2 years ago |
| SMA: Bullish | Mar 1, 2024 | 2 years ago |
| SMA: Bearish | Feb 28, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 24, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 23, 2024 | 2 years ago |
| RSI: Overbought | Jan 23, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 17, 2024 | 2 years ago |
| RSI: Overbought | Jan 8, 2024 | 2 years ago |
| RSI: Overbought | Jan 2, 2024 | 2 years ago |
| RSI: Overbought | Dec 14, 2023 | 2 years ago |
| SMA: Bullish | Nov 17, 2023 | 2 years ago |
| SMA: Bearish | Nov 16, 2023 | 2 years ago |
| SMA: Bullish | Nov 15, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 31, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 19, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 16, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 9, 2023 | 3 years ago |
| SMA: Bearish | Sep 29, 2023 | 3 years ago |
| SMA: Bullish | Sep 28, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 27, 2023 | 3 years ago |
| RSI: Oversold | Sep 25, 2023 | 3 years ago |
| RSI: Oversold | Sep 21, 2023 | 3 years ago |
| RSI: Oversold | Sep 15, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 5, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 21, 2023 | 3 years ago |
Key statistics
- Market cap
- 13.96M
- Enterprise value
- 3.82M
- Trailing P/E
- 0.00
- Forward P/E
- -2.41
- PEG ratio
- 0.00
- Price / sales
- 1396.08
- Price / book
- 0.36
- EPS (TTM)
- -0.62
- Beta
- 1.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 10.00K
- Revenue growth
- 0.00%
- Free cash flow
- -22.15M
- Total cash
- 22.39M
- Total debt
- 448.77K
- Return on equity
- -104.49%
- Shares outstanding
- 64.48M
- Short % of float
- 12.61%
- 50-day average
- 0.2958
- 200-day average
- 0.6851
Analyst view
Consensus: none
Price target (mean) 1.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 2, 2024
Expected Oct 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
GLYC Revenue — quarterly 0
GLYC Net income — quarterly -2.34M
GLYC EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.15 | — | — |
| Oct 2, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.16 | -0.17 | -0.01 | -6.25% |
| Mar 27, 2024 | Dec 1, 2023 | -0.15 | -0.14 | +0.01 | +6.67% |
| Nov 3, 2023 | Sep 1, 2023 | -0.14 | -0.14 | 0.00 | 0.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.18 | -0.13 | +0.05 | +27.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 26, 2024 | TD Cowen | down | Buy | Hold |
| Jun 4, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| May 6, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 22, 2023 | Capital One | init | — | Overweight |
| Aug 3, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- glycomimetics.com
News
- Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
- Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
- GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
- Crescent Biopharma Appoints David Lubner to Board of Directors
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
Your note
Sign in to keep a note on GLYC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDREWS PATRICIA S | Director | Stock Award(Grant) | Dec 28, 2023 | 58,608 |
| GOLDBERG MARK ALAN | Director | Stock Award(Grant) | Mar 27, 2024 | 36,325 |
| HAHN BRIAN M | Chief Financial Officer | Purchase | Jun 17, 2024 | 70,643 |
| INVUS PUBLIC EQUITIES ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 29, 2024 | 0 |
| JOHNSON BRUCE S | Officer | Purchase | May 7, 2023 | 138,980 |
| JUNIUS DANIEL M | Director | Stock Award(Grant) | Mar 27, 2024 | 98,459 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 14.80% | 9,544,262 | 2.07M | Sep 29, 2024 |
| Vanguard Group Inc | 4.14% | 2,670,208 | 578.10K | Sep 29, 2024 |
| Siren, L.L.C. | 3.05% | 1,965,114 | 425.45K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.21% | 781,100 | 169.11K | Sep 29, 2024 |
| Blackrock Inc. | 1.13% | 727,858 | 157.58K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 521,223 | 112.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 1,925,297 | 416.83K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.13% | 730,599 | 158.17K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 297,994 | 64.52K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 112,959 | 24.45K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 80,838 | 17.50K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 64,457 | 13.95K | Oct 30, 2024 |